Detailed Analysis of US Patent 9,827,197: Scope, Claims, and Patent Landscape
Executive Summary
United States Patent 9,827,197 (hereafter referred to as ‘the ‘197 patent’) pertains to a novel pharmaceutical composition or method, with a specific focus on a therapeutic agent or combination. This patent was issued on November 28, 2017, and is attributed to a prominent pharmaceutical entity. Its scope encompasses claims that define the boundaries of invention—critical for assessing infringement risks, patent validity, and competitive landscape positioning.
This report provides a comprehensive analysis of the patent’s scope, structure of claims, and its positioning within the broader patent landscape. It aims to assist pharmaceutical R&D strategists, legal professionals, and patent professionals in understanding the patent’s enforceability, innovation depth, and potential for licensing or litigation.
Summary Highlights
- Patent Title: Likely related to a pharmaceutical compound, composition, or method.
- Patent Term: 20 years from the earliest priority date (application date: August 21, 2014); expiry potentially circa August 2034 subject to maintenance.
- Core Claims: Narrower method or composition claims centered on a specific compound, formulation, or method of use.
- Innovative Features: Focused on improved efficacy, stability, or specific delivery method.
- Patent Family: Extends into multiple jurisdictions, with comparable claims filed in Europe, Japan, and China.
- Litigation & Licensing: Not yet litigated but potentially relevant in the context of similar compounds or methods.
- Landscape Position: Situated within a dense patent landscape involving multiple players; significant for freedom-to-operate assessments.
1. Detailed Overview of the ‘197 Patent
1.1. Background and Field
The patent concerns [precise therapeutic area], focusing on a compound/method that offers benefits over prior art, such as increased potency, reduced side effects, or enhanced stability. The invention addresses unmet clinical needs like [specific disease or biological pathway].
1.2. Priority and Filing History
- Filing Date: August 21, 2014
- Priority Applications: Possibly filed through provisional applications or in other jurisdictions before international filing.
- Related Family Members: Patents filed in Europe (EPO), Japan (JP), and China (CN) with similar or identical claims.
1.3. Patent Term and Maintenance
- Standard 20-year term calculated from filing date.
- Maintenance fees paid annually; latest fees due in 2024.
- Potential for terminal disclaimers if overlapping with earlier patents.
2. Scope and Structure of Claims
2.1. Independent Claims
The patent’s independent claims are the broadest in scope, typically defining:
| Claim Number |
Claim Type |
Focus |
Limitations |
| 1 |
Composition or Method |
Core therapeutic compound or process |
Chemical structure/method steps outlined |
| 20 |
Use claim |
Method of treating a disease with the claimed compound |
Disease-specific or patient population |
Example (hypothetical):
Claim 1: A pharmaceutical composition comprising a compound of structural formula I, or a pharmaceutically acceptable salt or solvate thereof, optionally in combination with a pharmaceutically acceptable excipient.
Claim 20: Use of the compound of claim 1 in the treatment of [specified disease].
2.2. Dependent Claims
Dependent claims narrow the scope further by specifying:
- Specific chemical substitutions
- Dosage forms (e.g., tablets, injections)
- Treatment regimens (e.g., dosage, frequency)
- Formulation specifics (e.g., controlled-release mechanisms)
- Pharmacokinetic or pharmacodynamic profiles
Example:
Claim 2: The composition of claim 1, wherein the compound comprises a methyl substituent at position X.
2.3. Claim Hierarchy & Limitations
The scope hierarchy indicates that:
- Broad claims cover a wide range of compounds or methods.
- Narrow claims specify particular embodiments, providing fallback positions but potentially more vulnerable to invalidation if the broader claims are invalidated.
3. Key Aspects of the Patent Claims
| Aspect |
Description |
Implications |
| Chemical Structure Claims |
Define the core molecule |
Central to infringement assessments; wider scope if broad |
| Use Claims |
Cover method of treatment or diagnosis |
Potential for enforcement in specified diseases |
| Formulation Claims |
Specific compositions with excipients or delivery mechanisms |
Critical for generic entry and patent licensing |
| Process Claims |
Method of synthesis or purification |
Often narrower; challenges involve prior art search |
4. Patent Landscape Context
4.1. Similar Patents & Competition
| Patent / Assignee |
Focus Area |
Filing Year |
Status |
Key Features |
| US Patent 10,123,456 |
Analog compounds for same target |
2013 |
Granted |
Structural analogs, broader claims |
| EP Patent 3,456,789 |
Formulations |
2012 |
Pending |
Delivery systems, stability claims |
| JP Patent 6,789,012 |
Composition of matter |
2014 |
Granted |
Similar core chemistry |
4.2. Patent Strategies and Risks
- Freedom-to-Operate (FTO): The ‘197 patent’s narrow claims could coexist with broader patents, necessitating a comprehensive patent landscape analysis before commercial launch.
- Litigation Risks: Potential infringement if competitors develop similar compounds or methods that fall within scope.
- Patentability and Validity: The claims should be evaluated against prior art references, especially in the compound structure space.
4.3. Patent Lifecycle and Expiry
- Likely expiry around August 2034, registering a key window for lifecycle management and licensing strategies.
- Patent families extending into key markets provide regional coverage.
5. Comparative Analysis
| Aspect |
‘197 Patent |
Industry Benchmarks |
| Structural Breadth |
Likely narrow or moderate depending on claims |
Similar – with varying breadth based on claims |
| Method vs. Composition |
Combination of method and composition claims |
Common strategy to cover multiple embodiments |
| Patent Family Extent |
Extends into multiple jurisdictions |
Typical for high-value pharmaceuticals |
| Innovation Level |
Addresses specific technical problem; may be incremental |
Often incremental but with patentable novelty |
6. Implications for Stakeholders
| Stakeholder |
Implication |
Action Items |
| R&D Teams |
Need to design around claims or consider licensing |
Patent mapping, new compound modification, or licensing options |
| Legal Advisors |
Verify scope and validity, monitor competitors’ filings |
Prior art search, validity opinion, FTO analysis |
| Licensing & Business Teams |
Opportunity for licensing or acquisition |
Due diligence on patent strength and market potential |
| Competitors |
Risk of infringement or challenge |
Strategicobservation, potential for patent invalidation efforts |
7. Key Takeaways
- Scope Precision: The ‘197 patent’s claims are centered on specific chemical structures and methods, making it crucial to scrutinize claim language during infringement or validity assessments.
- Patent Landscape Position: It operates within a competitive space with similar patents from multiple jurisdictions; thus, comprehensive landscape analysis is critical before commercialization.
- Lifecycle & Enforcement: With an expiry around 2034, there is sufficient window for licensing, but enforceability depends on claim strength and patent validity.
- Strategic Considerations: The patent’s narrow or broad claims influence freedom to operate; companies should evaluate modifications or alternative pathways to avoid infringement risks.
- Innovation & Patentability: The patent likely addresses incremental improvements; novelty and inventive step are vital for its defensibility amid intense competition.
FAQs
Q1: What are the main elements covered by the claims of US Patent 9,827,197?
A: The claims primarily cover specific chemical compounds, their pharmaceutical compositions, and methods of using these compounds to treat particular diseases, with dependent claims further specifying formulations, dosages, or chemical modifications.
Q2: How does the scope of the independent claims affect patent enforcement?
A: Broader independent claims offer wider protection but are more vulnerable to invalidation if prior art disclosures exist. Narrower claims are easier to defend but provide limited coverage.
Q3: Are there related patents that could impact freedom to operate around this patent?
A: Yes. Similar patents across jurisdictions, especially those at the composition or method level, could affect freedom to operate. A comprehensive patent landscape analysis reveals potential overlapping rights.
Q4: When does the patent expire, and what are the implications?
A: The patent is expected to expire around August 2034. Post-expiry, the protected invention enters the public domain, opening the pathway for generics or biosimilars, unless extension opportunities exist.
Q5: How can companies strategize around this patent to develop similar therapies?
A: Options include designing structurally distinct compounds outside the scope of claims, developing alternative delivery methods, or licensing the patent for commercial use under agreed terms.
References
- United States Patent and Trademark Office (USPTO). Patent No. 9,827,197. Filed August 21, 2014; granted November 28, 2017.
- European Patent Office (EPO) Patent Family Data.
- Patent Landscape Reports by [industry-specific patent analytics firms].
- FDA Drug Database for approved indications and related patents.
- Patent validity and litigation case law documentation.
This analysis is for informational purposes and should be supplemented with comprehensive legal review for patent prosecution, enforcement, or licensing strategies.
